surmount-1 tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Clinical trials of subcutaneous tirzepatide

Role of islet GLP-1 in alpha-cell heterogeneity Evidence that the alpha-cell proglucagon processing profile is dependent on the differential expression of PC1/3 versus PC2 suggests that alpha-cell GLP-1 production may function as a marker of alpha-cell heterogeneity

Chai, R

Baseline factors including age, hydration habits, fiber intake, existing IBS history, medications (opioids, anticholinergics), and genetic variants in GI peptide pathways all influence susceptibility

It should be noted that the amount of labeled amino acids (Cys+Met) in VP1 (7) is about one half of what it is in VP2 (14) or VP3 (17), therefore the VP1 band in the gel appears significantly lighter than the other two bands

doi: 10.1189/jlb.1003461 562 HuangYFLiuPYChenYYNongBRHuangIFHsiehKSet al

The 37 million Americans with type 2 diabetes and 108 million living with obesity wont see meaningful generic relief until at least 2031